(Q42634827)

4 November 2017

title

Phase II study of everolimus-erlotinib in previously treated patients with advanced non-small-cell lung cancer (English)

1 reference

4 November 2017

1 reference

B Besse

1

1 reference

4 November 2017

N Leighl

2

1 reference

4 November 2017

J Bennouna

3

1 reference

4 November 2017

V A Papadimitrakopoulou

4

1 reference

4 November 2017

N Blais

5

1 reference

4 November 2017

A M Traynor

6

1 reference

4 November 2017

J-C Soria

7

1 reference

4 November 2017

S Gogov

8

1 reference

4 November 2017

N Miller

9

1 reference

4 November 2017

V Jehl

10

1 reference

4 November 2017

B E Johnson

11

1 reference

4 November 2017

publication date

23 December 2013

1 reference

4 November 2017

1 reference

4 November 2017

volume

25

1 reference

4 November 2017

issue

2

1 reference

4 November 2017

page(s)

409-415

1 reference

The role of the molecular footprint of EGFR in tailoring treatment decisions in NSCLC.

4 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT536

Erlotinib in previously treated non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT536

Everolimus restores gefitinib sensitivity in resistant non-small cell lung cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT536

Overexpression of phospho-eIF4E is associated with survival through AKT pathway in non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT536

Development of PI3K/AKT/mTOR pathway inhibitors and their application in personalized therapy for non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT536

PI3K/PTEN/AKT/mTOR pathway genetic variation predicts toxicity and distant progression in lung cancer patients receiving platinum-based chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT536

Targeting epidermal growth factor receptor-associated signaling pathways in non-small cell lung cancer cells: implication in radiation response

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT536

Dual phosphoinositide 3-kinase/mammalian target of rapamycin blockade is an effective radiosensitizing strategy for the treatment of non-small cell lung cancer harboring K-RAS mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT536

Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT536

Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT536

Rationale for a phase I trial of erlotinib and the mammalian target of rapamycin inhibitor everolimus (RAD001) for patients with relapsed non small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT536

Everolimus and erlotinib as second- or third-line therapy in patients with advanced non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT536

Phase II trial of gefitinib and everolimus in advanced non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT536

Phase 1 trial of everolimus and gefitinib in patients with advanced nonsmall-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT536

Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT536

Everolimus for advanced pancreatic neuroendocrine tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT536

Natural history, management and pharmacokinetics of everolimus-induced-oral ulcers: insights into compliance issues.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT536

From theoretical synergy to clinical supra-additive toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT536

Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT536

Phase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT536

Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT536

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDT536

1 reference

4 November 2017

1 reference